Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19696795 | 0.74 | CHRM2 (0.34) | CHRM2MEN1CYP2D6KMT2ACHRM1 | |
| SCHEMBL14968394 | 0.73 | CHRM2 (0.33) | CHRM2MEN1CYP2D6KMT2ACHRM1 | |
| SCHEMBL21751436 | 0.71 | PRKD3 (0.44) | CHRM2MEN1CYP2D6KMT2ACHRM1 | |
| SCHEMBL789290 | 0.71 | PRKD3 (0.44) | CHRM2MEN1CYP2D6KMT2ACHRM1 | |
| SCHEMBL15870316 | 0.71 | PRKD3 (0.44) | CHRM2MEN1CYP2D6KMT2ACHRM1 | |
| SCHEMBL9958086 | 0.70 | CHRM2 (0.33) | CHRM2MEN1CYP2D6KMT2ACHRM1 | |
| SCHEMBL17279340 | 0.66 | CHRM2 (0.33) | METAP2CHRM2MEN1CYP2D6KMT2A | |
| SCHEMBL24145355 | 0.65 | POLB (0.38) | CHRM2MEN1CYP2D6KMT2ACHRM1 | |
| SCHEMBL5122258 | 0.65 | CHRM2 (0.38) | METAP2CHRM2MEN1CYP2D6KMT2A | |
| SCHEMBL220405 | 0.65 | POLB (0.38) | CHRM2MEN1CYP2D6KMT2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941435-B1 | MANNOSE-RECEPTOR SELECTIVE LYSINYLATED CATIONIC AMPHIPHILES AND A PROCESS FOR PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2021-06-16 | — | — | EP | disclosed |
| US-9840530-B2 | Mannose-receptor selective lysinylated cationic amphiphiles and a process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-12-12 | — | — | US | disclosed |
| EP-2616431-B1 | NOVEL CATIONIC AMPHIPHILES WITH MANNOSE-MIMICKING HEAD-GROUPS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-11-09 | — | — | EP | disclosed |
| US-20150337000-A1 | Mannose-Receptor Selective Lysinylated Cationic Amphiphiles and a Process for Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-11-26 | — | — | US | disclosed |
| US-8703824-B2 | Cationic amphiphiles with mannose-mimicking head-groups and a process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-04-22 | — | — | US | disclosed |
| EP-2616431-A1 | NOVEL CATIONIC AMPHIPHILES WITH MANNOSE-MIMICKING HEAD-GROUPS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2013-07-24 | — | — | EP | disclosed |
| US-20130129758-A1 | NOVEL CATIONIC AMPHIPHILES WITH MANNOSE-MIMICKING HEAD-GROUPS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-05-23 | — | — | US | disclosed |
| EP-2468741-A1 | Novel quercetin derivatives, their preparation, pharmaceutical compositions containing them and their use | Bel/Novamann International s.r.o. (SK) | 2012-06-27 | — | — | EP | disclosed |
| WO-2012035557-A1 | NOVEL CATIONIC AMPHIPHILES WITH MANNOSE-MIMICKING HEAD-GROUPS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-03-22 | — | — | WO | disclosed |
| WO-2009109996-A2 | NOVEL CATIONIC AMPHIPHILES WITH QUINIC ACID HEAD-GROUPS FOR DNA VACCINATION | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337000-A1 | Mannose-Receptor Selective Lysinylated Cationic Amphiphiles and a Process for Preparation Thereof | M6PR, MRGPRX2, MRGPRX1 | METAP2 326/4885CHRM2 810/4885MEN1 383/4885 |
| US-20130129758-A1 | NOVEL CATIONIC AMPHIPHILES WITH MANNOSE-MIMICKING HEAD-GROUPS AND A PROCESS FOR THE PREPARATION THEREOF | M6PR, CD14, MICA | METAP2 679/4885CHRM2 234/4885MEN1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.